ANTICANCER MEDICINE, CONTAINING α,α,α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR Russian patent published in 2010 - IPC A61K31/7068

Abstract RU 2394581 C2

FIELD: medicine.

SUBSTANCE: invention relates to medicine and deals with anticancer therapeutic medicine, which presents composition, containing α,α,α-trifluorothymidine (FTD) and 5-chlor-6-(1-(2-iminopyrrolidine)methyl)uracyl hydrochloride in molar ratio 1:0.5, and which is introduced to patient, who needs it, in dose, as in dose for FTD, 20-70 mg/m² /day two times per day - four times per day.

EFFECT: invention ensures anticancer therapeutic medicine of increased efficiency and safety.

12 cl, 2 ex, 2 dwg

Similar patents RU2394581C2

Title	Year	Author	Number
METHOD OF TREATING PATIENTS WITH CANCER WITH SEVERE RENAL INSUFFICIENCY	2017	Yoshida, Kenichiro	RU2727598C2
COMBINATION OF TRIFLURIDINE/TIPIRACIL HYDROCHLORIDE, ANTITUMOR PLATINUM COMPLEX, AND MODULATOR OF CONTROL POINTS OF IMMUNE RESPONSE	2018	Abastado Jean-Pierre Amellal Nadia Bruno Alain Burbridge Michael Frank Cattan Valerie Leger Catherine	RU2778887C2
ANTICANCER AGENT AND METHOD FOR PREDICTION OF THERAPEUTIC EFFECT FOR PATIENTS WITH COLON CANCER AND RECTUM GENE MUTATION KRAS	2012	Ito Masanobu Okabe Khiroyuki	RU2585528C2
ANTI-TUMOUR AGENT CONTAINING TAXANE COMPOUND AND ANTI-TUMOUR EFFECT ENHANCER	2015	Okabe, Hiroyuki	RU2693463C2
PREPARATION POTENTIATING RADIATION THERAPY	2007	Fukusima Masakazu	RU2435587C2
ANTITUMOUR DRUG CONTAINING ANTITUMOUR PLATINUM COMPLEX, AND ANTITUMOUR EFFECT ENHANCER	2015	Okabe, Hiroyuki	RU2678103C2
ANTITUMOUR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE	2014	Okabe Khiroyuki	RU2657604C2
ANTITUMOUR AGENT AND ANTITUMOUR EFFECT ENHANCER	2014	Okabe Khiroyuki	RU2682161C2
ORAL PHARMACEUTICAL COMPOSITION	2013	Okhnisi Josito Ogata Tetsuo	RU2639473C2
ORAL ADMINISTRABLE PHARMACEUTICAL COMPOSITION	2013	Okhnisi Josito	RU2600831C2

RU 2 394 581 C2

Authors

Emura Tomokhiro

Mita Akira

Dates

2010-07-20—Published

2006-01-25—Filed